Nanobiotix S.A. Announces Updates to JNJ-1900 (NBTXR3) Clinical Program

Nanobiotix S.A. has announced updates to the JNJ-1900 (NBTXR3) clinical development program following the transfer of sponsorship and operational control of the Phase 3 head and neck cancer trial to Johnson & Johnson (J&J). The company estimates that interim data from the NANORAY-312 trial will be analyzed and reported in the first half of 2027. Nanobiotix will continue to provide updates on JNJ-1900 (NBTXR3) clinical development, including studies sponsored by The University of Texas MD Anderson Cancer Center. JNJ-1900 (NBTXR3) is a novel oncology product composed of functionalized hafnium oxide nanoparticles, designed to induce significant tumor cell death when activated by radiotherapy. The product has shown potential in treating various solid tumors and is being evaluated in multiple clinical trials.